Rocket Lab secures 20 additional launches for Synspective, while Citi initiates coverage with a Buy rating and $105 price ...

Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn’t enough to ...

Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.

Citi analysts downgraded Moderna (MRNA) to a "sell" rating Wednesday, telling clients that the stock's "outsized" rally this ...

Citi downgraded Moderna to 'Sell' on valuation concerns after a massive 2026 rally, while investors await detailed Phase 3 ...

Citigroup is upgraded based on strong operating results and a somewhat improved starting valuation. Click to read more on the ...

Citigroup is getting hit harder than Bank of America despite the legal headline landing at Merrill Lynch, and the gap between ...

Citi Wealth would have welcomed a deeper stock-market correction this year, seeing any bigger pullback as an opportunity to buy.

Rocket Lab (RKLB) stock rises after Citi initiates a Buy rating and the company lands its largest-ever Electron launch deal.

Buyers are stepping into Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, evidently. The move comes one session after a ...

Citigroup stock falls 1.36% as Citi expands its Coinbase partnership with stablecoin payments, virtual accounts, and digital ...

Rocket Lab (RKLB) stock gains 3% after Citi initiates Buy rating with $105 target and company announces its largest-ever ...